

List of Figures:

Figure	Description	Page
Figure 2.1:	Generic phase diagram of surfactant-oil-water mixture showing the possible aggregates.	7
Figure 2.2:	The structure of micelles. M= Micelles for o/w microemulsion, RM= Reverse micelles for w/o microemulsion	17
Figure 2.3.:	The lamellae (L) and the spherulite (S) structures. The surfactant molecules in the spherulite are arranged as onion layers	18
Figure 2.4:	Bicontinuous structure. The "pipeline" forms an oil continuous phase and the exterior forms a water continuous phase	18
Figure 2.5.:	Possible microemulsion structures: a) Vesicles (adopted from ref. 10) b) interconnected rod-like micelles	19
Figure 2.6	Microemulsion base lecithin gels: (a) Schematic representation of the formation of lecithin gels upon addition of water to small phosphatidylcholine reverse micelles in apolar solvent. (b) Localisation of solubilised 'guest' molecules within lecithin gels. Lipophilic drug (stripped bar); hydrophilic drug (black circle) and amphiphilic drug (shaded head with attached tail)	19
Figure 2.7.:	A steric model correlating the shape of amphiphile to the spontaneous curvature of the interface. (Gennes, D et al., 1982)	26
Figure 2.8.:	Winsor Type I, Type II and Type III microemulsion	31
Figure 3.1	Absorptivity scans of acyclovir in 0.1 N HCl	103
Figure 3.2	Calibration curve of acyclovir in 0.1N HCl.	104
Figure 3.3	Absorptivity scan of acyclovir in ethanol	106
Figure 3.4	Calibration curve for the estimation of acyclovir	106
Figure 3.5	Absorptivity scan of acyclovir in PBS pH 7.4	108
Figure 3.6	Calibration curve for the estimation of acyclovir.	108
Figure 3.7	Absorptivity scan of efavirenz in methanol	113
Figure 3.8	Calibration curve for the estimation of efavirenz	114
Figure 3.9	Absorptivity scan of efavirenz in 1% SLS	116

Figure 3.10	Calibration curve for the estimation of efavirenz.	116
Figure 3.11	Calibration curve of efavirenz in standard solution	118
Figure 3.12	Calibration curve of efavirenz in rat plasma	120
Figure 3.13	Blank rat plasma peak for estimation of acyclovir in rat plasma	124
Figure 3.14	Acyclovir peak in water.	124
Figure 3.15	Acyclovir peak in rat blood plasma.	125
Figure 3.16	Calibration of acyclovir in rat plasma	126
Figure 3.17	Blank rat plasma peak for estimation of efavirenz in plasma	130
Figure 3.18	Efavirenz peak in mobile phase	130
Figure 3.19	Efavirenz peak in rat blood plasma.	130
Figure 4.1	Effect on interfacial tension (IFT) of oil in presence of ST, COST and ST+ COST mixture (System A)	146
Figure 4.2	Effect on interfacial tension (IFT) of oil in presence of ST, COST and ST+ COST mixture (System B)	148
Figure 4.3	Effect on interfacial tension (IFT) of oil in presence of ST, COST and ST+ COST mixture (System C)	150
Figure 4.4	Effect on interfacial tension (IFT) of oil in presence of ST, COST and ST+ COST mixture (System D)	152
Figure 4.5:	Pseudo-ternary phase diagram of labrasol, plurool olique, labrafac and water system (Km=4:1)	159
Figure 4.6	Pseudo-ternary phase diagram of labrasol, plurool olique, labrafac and water system (Km=3:1)	160
Figure 4.7	Pseudo-ternary phase diagram of labrasol, plurool olique, labrafac and water system (Km=2:1)	160
Figure 4.8	Pseudo-ternary phase diagram of tween 80, propylene glycol, labrafac and water system (Km=3:1)	161
Figure 4.9	Pseudo-ternary phase diagram of tween 80, propylene glycol, labrafac and water system (Km=2:1)	162
Figure 4.10	Pseudo-ternary phase diagram of tween 80, propylene glycol, labrafac and water system (Km=1:1)	162
Figure 4.11	Pseudo-ternary phase diagram of tween 80, propylene glycol,	163

	labrafac and water system ($K_m=1:2$)	
Figure 4.12	Pseudo-ternary phase diagram of labrasol, transcitol, labrafil M 1944CS and water system ($K_m=4:1$)	164
Figure 4.13	Pseudo-ternary phase diagram of labrasol, transcitol, labrafil M 1944CS and water system ($K_m=3:1$)	165
Figure 4.14	Pseudo-ternary phase diagram of labrasol, transcitol, labrafil M 1944CS and water system ($K_m=2:1$)	165
Figure 4.15	Pseudo-ternary phase diagram of labrasol, transcitol, labrafil M 1944CS and water system ($K_m=1:1$)	166
Figure 4.16	Pseudo-ternary phase diagram of Cremophor RH 40, propylene glycol, labrafil M 1944 CS and water system. ($K_m=3:1$)	167
Figure 4.17	Pseudo-ternary phase diagram of Cremophor RH 40, propylene glycol, labrafil M 1944 CS and water system ($K_m=2:1$)	167
Figure 4.18	Pseudo-ternary phase diagram of Cremophor RH 40, propylene glycol, labrafil M 1944 CS and water system ($K_m=1:1$)	168
Figure 4.19	Pseudo-ternary phase diagram of Cremophor RH 40, propylene glycol, labrafil M 1944 CS and water system ($K_m=1:2$)	168
Figure 5.1	Electrical conductivity as a function of water content (System A)	189
Figure 5.2	Electrical conductivity as a function of water content (System B)	190
Figure 5.3	Percolation threshold determination of system A (ST/COST ratio=4:1)	190
Figure 5.4	Percolation threshold determination of system A (ST/COST ratio=3:1)	191
Figure 5.5	Percolation threshold determination of system A (ST/COST ratio=2:1)	191
Figure 5.6	Percolation threshold determination of system B at different K_m	192
Figure 5.7	Electrical conductivity as a function of water content (System C)	194
Figure 5.8	Percolation threshold determination of system C at different K_m	194
Figure 5.9	Electrical conductivity as a function of water content (System D)	195
Figure 5.10	Percolation threshold determination of system D at different K_m	196
Figure 5.11	Viscosity changes with increasing water content at different	198

	surfactant to cosurfactant ratio (Km) (system A)	
Figure 5.12	Viscosity change with increasing % of aqueous phase (system B)	200
Figure 5.13	Viscosity changes with increasing water content at different surfactant to cosurfactant ratio (Km) (system C)	202
Figure 5.14	Viscosity changes with increasing water content at different surfactant to cosurfactant ratio (Km) (system D)	203
Figure 5.15	Comparative <i>in-vitro</i> diffusion profile of acyclovir through rat intestine from pure drug, tablet and microemulsion (AMEP)	214
Figure 5.16	<i>In-vitro</i> diffusion profile of acyclovir through rat intestine from microemulsion (BMEP)	216
Figure 5.17	<i>In-vitro</i> diffusion profile of acyclovir through rat intestine from microemulsion (C-MEP)	217
Figure 5.18	<i>In-vitro</i> diffusion profile of acyclovir through rat intestine from microemulsion (D-MEP)	219
Figure 5.19	Figure: TEM photograph of system A at Km=4	220
Figure 5.20	Figure: TEM photograph of system B at Km=2	220
Figure 5.21	Figure: TEM photograph of system C at Km=4	221
Figure 5.22	Figure: TEM photograph of system D at Km=2	221
Figure 6.1.:	Flow chart for the preparation of SLN	227
Figure 6.2.:	Response of factors at different level for Acy-SLN	237
Figure 6.3	Response of factors at different level for Efa-SLN	240
Figure 6.4.:	Particle size distribution of the acyclovir SLN (Batch No: ACY-SLN-opt 04)	241
Figure 6.5.:	Particle size distribution of the acyclovir SLN (Batch No: ACY-SLN-opt- 06)	242
Figure 6.6.:	Particle size distribution of the efavirenz SLN (Batch No- Ef-SLN-opt02)	242
Figure 6.7.:	Particle size distribution of the efavirenz SLN (Batch No- Ef-SLN-opt03)	242
Figure 6.8.:	DSC thermogram of pure acyclovir	246
Figure 6.9:	DSC thermogram of pure efavirenz	247

Figure 6.10:	DSC thermogram lipid (GDS)	247
Figure 6.11:	DSC thermogram of acyclovir loaded SLN	248
Figure 6.12:	DSC thermogram of lipid (GTS)	249
Figure 6.13:	DSC thermogram of efavirenz loaded SLN:	249
Figure 6.14:	Scanning Electron Micrograph of acyclovir loaded SLN (Acy-SLN-opt)	251
Figure 6.15:	Scanning Electron Micrograph of efavirenz loaded SLN.(Efa-SLN-opt)	251
Figure 6.16:	In-vitro diffusion of acyclovir from SLN formulations.	253
Figure 6.17:	Cumulative diffusion of acyclovir from different SLN formulation	254
Figure 6.18:	<i>In-vitro</i> diffusion of efavirenz from different SLN formulations.	256
Figure 6.19:	Cumulative diffusion of efavirenz from different SLN formulations	256
Figure 7.1:	Plasma concentration of acyclovir after i. v. administration	269
Figure 7.2:	Plasma concentration of acyclovir after oral administration	269
Figure 7.3:	Plasma concentration of efavirenz after i.v. administration	272
Figure 7.4:	Plasma concentration of efavirenz after oral administration	273
Figure 8.1.	Kidney from (a) control male rats showing normal morphology of epithelial cells located in the outer stripe of the outer media (b) rats treated with 20mg/kg/day acyclovir for 15days	282
Figure 8.2	Kidney from male rat treated with 20mg/kg/day acyclovir in (a) microemulsion (ME04) (b) microemulsion (ME11) for 15days	282
Figure 8.3	Kidney from male rat treated with 20mg/kg/day acyclovir in SLN (Acy-SLN-opt) for 15days.	283
Figure 8.4	Liver from (a) control male rats showing normal morphology (b) treated with 20mg/kg/day efavirenz for 15days	285
Figure 8.5	Liver from male rat treated with 20mg/kg/day efavirenz in (a) microemulsion (ME13) (b) microemulsion (ME23) for 15days	285
Figure 8.6	Liver from male rat treated with 20mg/kg/day efavirenz in SLN (Efa-SLN-opt) for 15days	286